Institut National de la Santé et de la Recherche Médicale (INSERM) U981, Villejuif, France.
J Clin Oncol. 2013 Jun 10;31(17):2167-72. doi: 10.1200/JCO.2012.47.7737. Epub 2013 Apr 29.
Characterization of the genomic changes that drive an individual patient's disease is critical in management of many cancers. In patients with non-small-cell lung cancer (NSCLC), obtaining tumor samples of sufficient size for genomic profiling on recurrence is often challenging. We undertook this study to compare genomic alterations identified in archived primary tumors from patients with NSCLC with those identified in metachronous or synchronous metastases.
Primary and matched metastatic tumor pairs from 15 patients were analyzed by using a targeted next-generation sequencing assay in a Clinical Laboratory Improvement Amendments laboratory. Genomic libraries were captured for 3,230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to high coverage.
Among 30 tumors, 311 genomic alterations were identified of which 63 were known recurrent (32 in primary tumor, 31 in metastasis) and 248 were nonrecurrent (likely passenger). TP53 mutations were the most frequently observed recurrent alterations (12 patients). Tumors harbored two or more (maximum four) recurrent alterations in 10 patients. Comparative analysis of recurrent alterations between primary tumor and matched metastasis revealed a concordance rate of 94% compared with 63% for likely passenger alterations.
This high concordance suggests that for the purposes of genomic profiling, use of archived primary tumor can identify the key recurrent somatic alterations present in matched NSCLC metastases and may provide much of the relevant genomic information required to guide treatment on recurrence.
鉴定驱动个体患者疾病的基因组变化对于许多癌症的治疗至关重要。在非小细胞肺癌(NSCLC)患者中,获取足够大小的肿瘤样本进行基因组分析以预测复发常常具有挑战性。我们进行了这项研究,旨在比较 NSCLC 患者存档的原发性肿瘤和同时性或异时性转移灶中鉴定出的基因组改变。
通过在临床实验室改进修正案(CLIA)实验室中使用靶向下一代测序检测,对 15 名患者的原发性和配对转移性肿瘤对进行了分析。对 182 个癌症相关基因的 3230 个外显子和 14 个经常在癌症中重排的基因的 37 个内含子进行了基因组文库捕获,并进行了高覆盖率测序。
在 30 个肿瘤中,鉴定出 311 个基因组改变,其中 63 个是已知的复发性改变(原发性肿瘤中 32 个,转移灶中 31 个),248 个是非复发性改变(可能是乘客)。TP53 突变是最常见的复发性改变(12 例患者)。10 例患者的肿瘤中存在两个或更多(最多四个)复发性改变。原发性肿瘤和配对转移灶中复发性改变的比较分析显示,与可能的乘客改变的 63%相比,一致性率为 94%。
这种高一致性表明,对于基因组分析目的,使用存档的原发性肿瘤可以鉴定出匹配的 NSCLC 转移灶中存在的关键复发性体细胞改变,并可能提供指导复发治疗所需的大部分相关基因组信息。